BioAtla, Inc. (BCAB) vs Valion Bio, Inc. (VBIO)

BioAtla, Inc. and Valion Bio, Inc. are both Biotechnology companies. BioAtla, Inc. and Valion Bio, Inc. are of similar size ($3.0M and $2.9M). BioAtla, Inc. grew revenue faster over the last twelve months: 574.7% against −49.6%. Valion Bio, Inc. has the higher net margin (0.00% vs −177.2%) and the lower return on invested capital (−61.0% vs 0.00%). Across the 17 metrics below, BioAtla, Inc. leads on 10 and Valion Bio, Inc. on 7.

Valuation

Metric BCAB VBIO Biotechnology median
P/E n/m n/m 7.88
P/S 0.14 0.84 11.47
P/B n/m 0.10 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 0.21 11.80 10.73
Earnings yield (1,719.59%) (6,048.69%) (28.84%)
Free cash flow yield (959.44%) (3,751.73%) (23.03%)

Profitability

Metric BCAB VBIO Biotechnology median
Gross margin 95.44% (58.09%) 65.16%
Operating margin (180.99%) 0.00% 0.00%
Net margin (177.21%) 0.00% 0.00%
Free cash flow margin (132.29%) 0.00% 0.00%
Return on equity 118.74% (489.30%) (57.72%)
Return on assets (171.72%) (104.96%) (49.22%)
Return on invested capital 0.00% (61.01%) 0.00%

Growth

Metric BCAB VBIO Biotechnology median
Revenue growth (TTM) 574.65% (49.63%) 5.64%
EPS growth (last fiscal year) 29.86% 60.16% —
Revenue growth, 5-year CAGR (28.40%) 13.18% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCAB VBIO Biotechnology median
Debt to equity 0.00 0.62 0.00
Current ratio 0.20 1.11 4.73
Net debt to EBITDA 0.12 0.79 0.96

Dividend

Metric BCAB VBIO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCAB VBIO Biotechnology median
Market cap 2.89m 2.97m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack